iX Biopharma Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Eddy Lee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	16.8yrs
Eigendom CEO	22.3%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

CEO

Eddy Lee (70 yo)

16.8yrs

Tenure

Mr. Yip Hang Lee, also known as Eddy, serves as the Chief Executive Officer of iX Biopharma Ltd. and has been its Executive Chairman since January 17, 2008. Mr. Lee is responsible for running the affairs o...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chin Beng Lim	Chief Pharmacist	3.8yrs	geen gegevens	geen gegevens
Yip Hang Lee	Executive Chairman & CEO	no data	geen gegevens	22.25% SGD 4.7m
Sien Lup Chew	Chief Financial Officer	8.6yrs	geen gegevens	geen gegevens
Janakan Krishnarajah	COO & Chief Medical Officer	5.6yrs	geen gegevens	0.69% SGD 146.2k
Iain Cook	Chief Scientist	9.2yrs	geen gegevens	geen gegevens
Eva Tan	Chief Commercial Officer	3.8yrs	geen gegevens	geen gegevens
Kuan Loong Lai	Secretary	2.8yrs	geen gegevens	geen gegevens
Soo Fern Lee	Secretary	2.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 42C wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yip Hang Lee	Executive Chairman & CEO	16.8yrs	geen gegevens	22.25% SGD 4.7m
Patrick Donald Davies	Non-Executive Lead Independent Director	4.9yrs	geen gegevens	geen gegevens
Shing Tung Ho	Non-Executive Non-Independent Director	11.7yrs	geen gegevens	1.26% SGD 267.3k
Bob Rappaport	Member of Scientific Advisory Board	8.6yrs	geen gegevens	geen gegevens
Stephan A. Schug	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Yandi Liu	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Woon Keng Teo	Independent Non-Executive Director	2yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 42C wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

iX Biopharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

iX Biopharma Ltd. Announces Reconstitution of the Board Committees

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

Recent updates

iX Biopharma Ltd. Announces Reconstitution of the Board Committees

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024

Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023)

New minor risk - Financial data availability

New minor risk - Shareholder dilution

New major risk - Financial position

iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023

Full year 2023 earnings released: S$0.013 loss per share (vs S$0.006 loss in FY 2022)

New major risk - Share price stability

New minor risk - Financial data availability

iX Biopharma Ltd. announced that it has received SGD 2 million in funding

iX Biopharma Ltd. announced that it expects to receive SGD 2 million in funding

First half 2023 earnings released: S$0.01 loss per share (vs S$0.005 profit in 1H 2022)

iX Biopharma Ltd Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

Forecast to breakeven in 2024

iX Biopharma Ltd. Announces Board and Committee Appointment

iX Biopharma Ltd., Annual General Meeting, Oct 14, 2022

Full year 2022 earnings released: S$0.006 loss per share (vs S$0.012 loss in FY 2021)

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 2.742 million.

iX Biopharma Ltd. Announces Drug Development Updates for Wafermine and Wafesil

iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd

Price target decreased to S$0.34

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iX Biopharma Ltd. Announces Executive Changes

iX Biopharma Ltd Appoints Angeline Tham as Non-Executive Independent Director, Member of Audit Committee and Remuneration Committee and Chairperson of Nominating Committee, Effective 1 February 2022

No longer forecast to breakeven

Price target decreased to S$0.34

Full year 2021 earnings released: S$0.012 loss per share (vs S$0.016 loss in FY 2020)

Full year 2021 earnings released: S$0.008 loss per share (vs S$0.016 loss in FY 2020)

Executive Chairman & CEO exercised options to buy S$2.7m worth of stock.

iX Biopharma Ltd to Participate in Study with Wafermine for Treatment of Breakthrough Pain in Advanced Cancer Patients

iX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs

First half 2021 earnings released: S$0.004 loss per share (vs S$0.009 loss in 1H 2020)

iX Biopharma Ltd. Appoints Ms. Eva Tan as Its New Chief Commercial Officer

Full year earnings released - S$0.016 loss per share

New 90-day low - S$0.23

iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 10.232999 million.

Full year earnings released

New 90-day high - S$0.34

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd